Efficacy and Safety of Vonoprazan-Based Dual Therapies With Different Antibiotics Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Four-Arm, Randomized Controlled Trial
Two-drug stomach ulcer treatments work as well as older four-drug regimens but cause fewer side effects, offering simpler options.
This 4-arm RCT demonstrates that vonoprazan-amoxicillin (VA) and vonoprazan-minocycline (VM) dual therapies achieve eradication rates comparable to bismuth quadruple therapy (BQT) with fewer adverse events, potentially offering simpler and better-tolerated first-line H. pylori eradication options. Findings are exploratory and warrant confirmation in larger adequately powered trials.
What the study was
- Study design
- Prospective 4-arm RCT
- Population
- H. pylori-infected patients, 2 centers China, n=400 (100 per arm: VA, VT, VM, VACB)
- Sample size
- 400
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Helicobacter
Why it surfaced
Well-designed RCT comparing vonoprazan regimens vs BQT in a clinically significant area. Vonoprazan-based simplification of H. pylori therapy is a near-term implementable advance. Adjacent to watchlist via hematologic implications (H. pylori → ITP, MALT).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.